Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CERS
HoldHot AirCerus Corporation · Healthcare · United States · $534M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Cerus Corporation is a biomedical products company focused on blood safety, developing and commercializing the INTERCEPT Blood System, a proprietary technology designed to inactivate a broad spectrum of pathogens in transfused blood components. Its competitive moat lies in its patented technology, offering a critical safety enhancement in transfusion medicine with significant regulatory approvals and growing adoption by blood centers globally. Cerus is a niche leader, driving innovation in blood component safety with a unique and effective solution.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 162.0M | 156.4M | 180.3M | 206.1M | 8.4% | 221.6M | 249.0M | 271.5M | 14.8% |
| EPS | -0.24 | -0.21 | -0.11 | -0.08 | — | -0.03 | -0.05 | -0.01 | — |
| Shares | 177.6M | 181.2M | 185.8M | 192.1M | +8.2% | 201.5M | — | — | — |
| Debt | 87.2M | 96.0M | 98.1M | 96.9M | 3.6% | 76.8M | — | — | — |
| Equity | 67.6M | 52.6M | 56.1M | 64.2M | -1.7% | — | — | — | — |
| Op CF | -25.6M | -43.2M | 11.4M | 4.8M | -57.4% | 2.4M | — | — | — |
| Inv CF | 8.5M | 8.6M | -8.1M | -6.2M | — | — | — | — | — |
| Fin CF | 4.2M | 10.7M | 5.0M | 0.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CERS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CERS | Cerus Corporation(you) | $534M | 37 | Hold |
| NPCE | NeuroPace, Inc. | $495M | 32 | Sell |
| CTKB | Cytek Biosciences, Inc. | $608M | 32 | Sell |
| KIDS | OrthoPediatrics Corp. | $617M | 41 | Hold |
| SENS | Senseonics Holdings, Inc. | $493M | 29 | Sell |
| SGHT | Sight Sciences, Inc. | $471M | 44 | Hold |
| AHCO | AdaptHealth Corp. | $772M | 41 | Hold |
| TMCI | Treace Medical Concepts, Inc. | $302M | 39 | Hold |
| MASS | 908 Devices Inc. | $444M | 48 | Hold |
| OFIX | Orthofix Medical Inc. | $392M | 27 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%